Cargando…

What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron †

This review provides a synopsis of the published literature over the past two years on the heme-binding protein hemopexin (HPX), with some background information on the biochemistry of the HPX system. One focus is on the mechanisms of heme-driven pathology in the context of heme and iron homeostasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Montecinos, Luis, Eskew, Jeffrey D., Smith, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958331/
https://www.ncbi.nlm.nih.gov/pubmed/31554244
http://dx.doi.org/10.3390/ph12040144
_version_ 1783487388945743872
author Montecinos, Luis
Eskew, Jeffrey D.
Smith, Ann
author_facet Montecinos, Luis
Eskew, Jeffrey D.
Smith, Ann
author_sort Montecinos, Luis
collection PubMed
description This review provides a synopsis of the published literature over the past two years on the heme-binding protein hemopexin (HPX), with some background information on the biochemistry of the HPX system. One focus is on the mechanisms of heme-driven pathology in the context of heme and iron homeostasis in human health and disease. The heme-binding protein hemopexin is a multi-functional protectant against hemoglobin (Hb)-derived heme toxicity as well as mitigating heme-mediated effects on immune cells, endothelial cells, and stem cells that collectively contribute to driving inflammation, perturbing vascular hemostasis and blood–brain barrier function. Heme toxicity, which may lead to iron toxicity, is recognized increasingly in a wide range of conditions involving hemolysis and immune system activation and, in this review, we highlight some newly identified actions of heme and hemopexin especially in situations where normal processes fail to maintain heme and iron homeostasis. Finally, we present preliminary data showing that the cytokine IL-6 cross talks with activation of the c-Jun N-terminal kinase pathway in response to heme-hemopexin in models of hepatocytes. This indicates another level of complexity in the cell responses to elevated heme via the HPX system when the immune system is activated and/or in the presence of inflammation.
format Online
Article
Text
id pubmed-6958331
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69583312020-01-23 What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron † Montecinos, Luis Eskew, Jeffrey D. Smith, Ann Pharmaceuticals (Basel) Review This review provides a synopsis of the published literature over the past two years on the heme-binding protein hemopexin (HPX), with some background information on the biochemistry of the HPX system. One focus is on the mechanisms of heme-driven pathology in the context of heme and iron homeostasis in human health and disease. The heme-binding protein hemopexin is a multi-functional protectant against hemoglobin (Hb)-derived heme toxicity as well as mitigating heme-mediated effects on immune cells, endothelial cells, and stem cells that collectively contribute to driving inflammation, perturbing vascular hemostasis and blood–brain barrier function. Heme toxicity, which may lead to iron toxicity, is recognized increasingly in a wide range of conditions involving hemolysis and immune system activation and, in this review, we highlight some newly identified actions of heme and hemopexin especially in situations where normal processes fail to maintain heme and iron homeostasis. Finally, we present preliminary data showing that the cytokine IL-6 cross talks with activation of the c-Jun N-terminal kinase pathway in response to heme-hemopexin in models of hepatocytes. This indicates another level of complexity in the cell responses to elevated heme via the HPX system when the immune system is activated and/or in the presence of inflammation. MDPI 2019-09-24 /pmc/articles/PMC6958331/ /pubmed/31554244 http://dx.doi.org/10.3390/ph12040144 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Montecinos, Luis
Eskew, Jeffrey D.
Smith, Ann
What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron †
title What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron †
title_full What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron †
title_fullStr What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron †
title_full_unstemmed What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron †
title_short What Is Next in This “Age” of Heme-Driven Pathology and Protection by Hemopexin? An Update and Links with Iron †
title_sort what is next in this “age” of heme-driven pathology and protection by hemopexin? an update and links with iron †
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958331/
https://www.ncbi.nlm.nih.gov/pubmed/31554244
http://dx.doi.org/10.3390/ph12040144
work_keys_str_mv AT montecinosluis whatisnextinthisageofhemedrivenpathologyandprotectionbyhemopexinanupdateandlinkswithiron
AT eskewjeffreyd whatisnextinthisageofhemedrivenpathologyandprotectionbyhemopexinanupdateandlinkswithiron
AT smithann whatisnextinthisageofhemedrivenpathologyandprotectionbyhemopexinanupdateandlinkswithiron